Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.41 |
| ▸ | CSF1R | P07333 | 2/20 | 0.41 |
| ▸ | RAF1 | P04049 | 1/20 | 0.41 |
| ▸ | LYN | P07948 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | ACVR1 | Q04771 | 3/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12552677 | 0.99 | ALDH1A1 (0.55) | ALDH1A1SMN1; SMN2DDR1FFAR4CSF1R | |
| SCHEMBL1420647 | 0.89 | L3MBTL3 (0.48) | ALDH1A1FFAR4HTR7TACR1 | |
| SCHEMBL12552629 | 0.88 | L3MBTL3 (0.49) | ALDH1A1FFAR4HTR7TACR1 | |
| SCHEMBL1962802 | 0.87 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2DDR1FFAR4CSF1R | |
| SCHEMBL12552649 | 0.87 | USP2 (0.49) | ALDH1A1SMN1; SMN2DDR1FFAR4TACR1 | |
| SCHEMBL12552645 | 0.87 | L3MBTL3 (0.48) | ALDH1A1FFAR4TACR1 | |
| SCHEMBL502328 | 0.86 | DDR1 (0.49) | ALDH1A1SMN1; SMN2DDR1FFAR4CSF1R | |
| Hydrochloric Acid SCHEMBL397746 | 0.85 | DDR1 (0.48) | ALDH1A1SMN1; SMN2DDR1FFAR4CSF1R | |
| SCHEMBL20577959 | 0.81 | USP2 (0.56) | SMN1; SMN2FFAR4CSF1R | |
| SCHEMBL10104363 | 0.80 | ALDH1A1 (0.61) | ALDH1A1SMN1; SMN2FFAR4ACVR1HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110144107-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF MALARIA | IRM LLC (BM) | 2011-06-16 | — | — | US | disclosed |
| EP-2297097-A2 | COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF MALARIA | IRM LLC (BM) | 2011-03-23 | — | — | EP | disclosed |
| WO-2009152356-A2 | COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF MALARIA | IRM LLC (BM) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144107-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF MALARIA | G6PD, DHFR, SGMS1 | ALDH1A1 1547/4885SMN1; SMN2 2609/4885DDR1 4834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.